AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: AMY REEVES
When NitroMed recently announced that its heart-failure drug BiDil showed strong trial results, Wall Street smelled money. The stock price tripled the next week.
That wasn't the only reason BiDil made news. It also was the first heart drug tested entirely on African-Americans.
Black Americans suffer a higher rate of heart disease than any other ethnic group. Though they make up only 11% of the population, they bear 18% of the heart-disease burden. Yet heart medicines have not served them as well.
By and large, blacks seem to have the disease for different reasons than other ethnic groups. It's more likely related to hypertension than it is to coronary blockage.
Blacks take standard drugs such as Ace inhibitors, yet studies show those drugs don't work as well on them as on others.
The first developers of BiDil weren't even looking to make a drug for blacks.